Walking ability in patients with glioblastoma: prognostic value of the Berg Balance Scale and the 10 meter walk test

Monique Mesot Liljehult, Lise Buus, Jacob Liljehult, Birthe Krogh Rasmussen

Publikation: Bidrag til tidsskriftTidsskriftsartikelForskningpeer review


Primary brain tumors frequently cause considerable functional impairments and the survival time when diagnosed with glioblastoma is 14.6 months. The aim of this study was to examine if baseline postural control and walking ability in patients with glioblastoma could predict long term walking ability and 1 year mortality. Data were gathered from prospective recordings in a brain cancer database supplemented by retrospective review of electronic patient records. We included 109 patients with glioblastoma, 47 women and 62 men with mean age 65 years. At admission 84 patients were tested with Berg Balance Scale and 57 were tested with 10 meter walk test. Binary logistic regression analysis showed no statistical significance in favour of the 10 meter walk test. Berg Balance Scale showed an ability to predict walking ability 4-8 months after admission. The risk of dying within a year was 6.9 times higher in patients who lost their ability to walk within 4-8 months of the first admission. This study showed that Berg Balance Scale has some ability to predict the loss of walking ability 4-8 months after admission. This could be an important indicator pin pointing patients most in need of more intensive specialized neurorehabilitation efforts early in the disease course.

TidsskriftJournal of Neuro-Oncology
Udgave nummer2
Sider (fra-til)335-342
Antal sider8
StatusUdgivet - nov. 2017
Udgivet eksterntJa